Objectives: Using a national data set, we sought to assess patterns of pessary care in older women with pelvic organ prolapse (POP) and subsequent outcomes, including rates of complications and surgical treatment of POP.
P elvic organ prolapse (POP) is a common medical condition that negatively affects the quality of life of many women. 1 Pelvic floor disorders, including POP, urinary incontinence, and fecal incontinence, affect almost a quarter of the adult female population in the United States. 1 This incidence increases to almost 50% among women older than 80 years. The US Census Bureau projects that the number of women 65 years old and older will double and exceed 40 million by the year 2030. 2 With the aging US population, there has been a renewed interest in the use of nonsurgical treatments for POP. A survey distributed to members of the American Urogynecologic Society in 2000 showed that 77% of respondents offered pessaries to their patients as a first-line therapy for POP. 3 Most women with symptomatic POP also choose a pessary over surgery as their initial treatment. 4 Pessaries have been used to treat POP since the beginning of recorded medical history. Hippocrates suggested the use of half of a pomegranate for ''womb prolapse'' in the fifth century BC. Despite the evolution of various other treatments for POP through the centuries, pessaries remain a viable and practical option. There are very few contraindications to their use, which allows physicians to offer pessaries to almost all patients presenting with prolapse. 5, 6 Although pessary is a low-risk, minimally invasive treatment option for POP, complications can occur with its use. Most are mild, such as odor or discharge; however, complications associated with high morbidity, such as fistulas, pessary impaction, vaginal fibrosis with stricture, and enterocele rupture with vaginal evisceration, have been reported. 7Y11 Despite being a first-line therapy for many patients, there are currently no clear guidelines on the management of women with pessaries. This study used a national data set to identify patterns of pessary care and subsequent safety and effectiveness outcomes, including rates of complications and pessary discontinuation requiring surgery for prolapse repair.
MATERIALS AND METHODS
Upon review of the protocol for this retrospective analysis of de-identified longitudinal patient data, an exemption was obtained from the Institutional Review Board at the University of California, Los Angeles. Women with the diagnosis of POP in 1999Y2000 were identified from a 5% national random sample of Medicare beneficiaries from the public use files provided by the Centers for Medicare and Medicaid Services. Subjects were selected to be in the 5% beneficiary sample based on the last 2 digits of their Medicare health insurance claim number. Medical care and outcomes were identified based on diagnosis and procedure codes according to the International Classification of Disease, 9th edition, Clinical Modification (ICD-9-CM) system or of procedure codes according to the Current Procedural Terminology, 4th Edition (CPT-4) system. Subjects receiving a pessary were identified if they had a code for pessary placement (57160) during the 2-year index period. Individual de-identified subjects were longitudinally tracked for 9 years, through 2009. Follow-up clinic visits (99211Y99215) and repeat pessary placements (51760) were used to identify and measure follow-up (Appendix 1). The nonspecific nature of the 99211Y99215 codes does not guarantee that patients underwent a pelvic examination at the time of these visits; therefore, we specifically analyzed follow-up by provider type.
Because the 57160 code is used for fitting of a new pessary, repeated pessary exchanges were considered to have occurred if a follow-up clinic visit took place, which might artificially inflate the presumed rate of follow-up that includes pessary care. The ''vaginal irrigation after pessary'' code was encountered infrequently but was considered to indicate a follow-up pessary visit as well. To further increase accuracy, repeated follow-up clinic visits were determined for specific specialties as well as for the same provider who placed the initial pessary. Pessary changes were evaluated quarterly for the first 2 years and annually thereafter. The rates of complications and outcomes, identified by ICD-9 and CPT-4 codes, including mechanical device complications and the rate of surgery for POP, were determined within the same time interval (Appendix 2). Demographic and clinical characteristics, including comorbidities and complication rates, were obtained from an analytical file created by linking encrypted beneficiary identification numbers from 3 Medicare standard analytic files representing hospital inpatient, hospital outpatient, and physician-supplier part B care. 12, 13 International Classification of Disease, 9th edition, Clinical Modification codes were used to calculate Charlson scores to measure comorbidity. The Charlson score is an index totaling scores from 19 weighted comorbidities to predict the likelihood of 1-year mortality for a patient. A higher score indicates greater comorbidity. 14 All descriptive analyses were conducted using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS
The total number of randomly sampled Medicare beneficiaries from which we drew our cohort was 825,000. The study population consists of 34,782 (4.2%) women with the diagnosis of POP. Of the 34,782 women with the diagnosis of POP in 1999Y2000, 4019 (11.6%) were treated with a pessary. Twentyfour percent underwent surgery for POP (half of which had the surgery in the first year). Most of the POP surgery was reconstructive, with only 3% rate of an obliterative procedure (colpocleisis). Apical repair was the most commonly performed prolapse repair performed. The second most common procedure was a combined anterior and posterior colporrhaphy followed by an anterior colporrhaphy alone.
Most of the pessary recipients were white (94%). Main comorbidities identified in this cohort were diabetes (10%), congestive heart failure (9%), malignancy (7%), chronic respiratory disease (5%), dementia (3%), renal disease (2%), and cerebrovascular disease (3%). However, most women (95%) had a Charlson score of 3 or less ( Table 1 ). The all-cause mortality rate through 9 years was 30.4%.
The prevalence of prolapse treatment with pessaries seemed to be uniform throughout the United States, with a slightly higher rate of 15% in the northeastern region of the country. Among the pessary users, the rates of placement progressively increased with age from 4.9% in women aged 65 to 69 to 24.7% in the group 85 and older. Most of the pessaries were placed by gynecologists (84%), 3.8% were placed by a provider in a multi-specialty or group practice, 3.5% by urologists, and 3% by an internist or family practitioner ( Table 2 ).
In the initial 3 months after pessary placement, 40% underwent a follow-up visit with the provider who had placed the pessary, and through the 9 years after the procedure, 69% had such a visit. Overall rate of follow-up (by any provider, and therefore not specific to pessary follow-up) was 84% in the first 3 months and 98% at 9 years (Table 3 ).
In the ensuing 9 years after pessary placement, 3% of the subjects developed vesicovaginal or rectovaginal fistulas and 5% had a complication due to a mechanical genitourinary device. The most common complications diagnosed within the first 3 months after initial pessary placement are urinary tract infections (19%) followed by vaginitis (6%). Urinary tract infections were documented in 86% and vaginitis in 35% of patients fitted with pessaries through the 9 years of follow-up. Over time, a large percentage of women acquired a diagnosis of (or treatment for) urinary retention. Rates of dyspareunia also increased over time (Table 4 ).
DISCUSSION
Pessaries offer a low-morbidity, minimally invasive treatment option for women with symptomatic POP while achieving comparable rates of success compared to surgical outcomes. 6, 15 They are cited as being a preferred first-line treatment option for POP by both health care providers and patients and often serve as definitive treatment for those who are poor surgical candidates. 3, 4 The mortality rate of 30.4% at 9 years exceeded the rate of surgical repair during that time (24%) in this cohort. Thus, our study confirms that pessaries represent an appropriate and often definitive treatment for many older women. However, despite these and contrary to the results of surveys and polls, our study highlights a low use of pessaries in women aged 65 years and older. In our analysis of more than 34,000 women with POP, only 11.6% were identified as being treated with a pessary. Unfortunately, the ICD-9 codes for POP do not currently have modifiers, thus not allowing to ascertain the severity of prolapse or the degree of symptoms. Thus, it is possible that a low rate of pessary use in our study is partially due to the inclusion of asymptomatic patients with diagnosis of POP who did not require treatment; but given the limitations of the data available to us, we are unable to deduce a precise reason for such low use of pessary in the treatment of POP. Our study population of 34,782 women with the diagnosis of POP constituted only 4.2% of the total number of randomly sampled Medicare beneficiaries from which we drew our cohort. Recently published epidemiological studies have shown a 7% prevalence of POP at or distal to the hymen in general population of women with median age of 42 years (18Y83 years). 16 Several studies have now shown that symptoms due to POP develop when the leading edge is at or distal to the hymen. 17, 18 Age is a well-established risk factor for POP progression. 19 5  8  10  12  15  20  21  24  Colpocleisis  0  1  1  1  2  2  2  3  Anterior  2  2  3  3  4  6  6  8  Anterior and posterior  2  4  5  6  8  10  11  12  Anterior and posterior and apical  1  1  1  2  2  3  3  3  Posterior  1  2  2  3  3  4  5  5  Apical  4  6  7  8  11  14  15  18  Mesh insertion  0  0  0  0  0  0  0  1  Complications  UTI  19  30  38  44  58  73  77  86  Vaginitis  6  9  12  14  20  27  29  35  Dyspareunia  8  12  15  17  24  32  34  41  Retention of urine  2  4  5  6  8  12  13  18  Mechanical complication Thus, we do not think that the patients with asymptomatic POP represented a significant enough portion of our cohort to account for the low rate of pessary use. Furthermore, our data point to a possibility that the number of women with symptomatic POP prolapse is likely underdiagnosed among Medicare beneficiaries in the real world. Pessaries have been a viable treatment for POP for centuries 20 ; with no clear guidelines for pessary fitting, follow-up, or management established to date. We found that most of the women treated with a pessary had a subsequent follow-up visit either with the same provider and/or a gynecologist. However, a significant minority seemed not to have continuity of care. The sequelae of this lack of continuity of care may include an unacceptable rate of vaginal fistula formation. Although the diagnoses of fistula may result from inflammatory bowel disease, abdominopelvic surgery, malignancy, and radiation treatment, it seems plausible that, at least, some of these fistulae were likely related to a forgotten pessary.
Proposed protocols for pessary follow-up usually come from the pessary manufacturer; some suggest follow-up every 4 to 6 weeks, which can be very burdensome and costly to patients. Variables in management to consider include timing to follow-up after the initial fitting, the frequency of follow-ups thereafter, use of hormone replacement therapy in postmenopausal women, the type of pessary placed, and additional conservative options for unsuccessful pessary trials. Published reports on the length of follow-up after the initial pessary fitting vary from 1 to 3 weeks to assess for successful fitting. 12,13,21Y23 Subsequent follow-up intervals also vary greatly in the literature, from every 3 months to annually for those who are able to perform self-care 12,21Y25 to 1 to 3 months for those who are not. 24 We recently developed quality-of-care indicators for POP management, and, using the RAND appropriateness method, 26Y27 it was determined that patients with a pessary should have a pelvic examination by a physician at least once every 6 months (unpublished data).
The strength of our study lies in the fact that claims data allow for analysis of a large sample of patients with a broad geographic distribution. Long-term follow-up is another invaluable aspect of archival data. Both the large sample size and the 9-year longitudinal follow-up allowed us to examine the risk of rare complications related to pessary use as well as the rates of conversion to surgical management of prolapse over time.
The limitations of our research are inherent in the study design, with accuracy of the data dependent on proper coding by the providers. Our analyses were further limited by a paucity of clinical details, such as severity of prolapse or degree of symptoms and inability to know with certainty if complications of interest were directly caused by the pessary use. The biggest limitation in assessing the frequency of follow-up lies in the fact that the CPT-4 procedure code for pessary fitting (57160) applies to fittings of a new pessary per Medicare rules and regulations. Because reimbursement for services was dependent on appropriate coding, providers were incentivized to accurately report their services through the available codes. However, lack of a pessary exchange/cleaning code may preclude an accurate assessment of pessary follow-up care using these national claims data sets. Electronic health records conceivably could provide more information; however, the sample sizes available to date are relatively small. In addition, because the Medicare data we analyzed were limited to patients 65 year and older, no information is available on those younger than 65.
This study provides real-world evidence of pessary use for management of POP among elderly Americans. Effectiveness of pessaries is suggested by the relatively modest subsequent surgery rate, whereas the low rates of complications confirm the safety of this treatment modality. Future analyses should identify whether the low pessary placement rate and lack of continuity of care in this population still exist. Large prospective studies are warranted to further examine outcomes of pessary use. Based on the data from such trials, clear guidelines on frequency of follow-up after pessary placement can be determined. Optimal pessary management protocols will balance timing and frequency of follow-up while minimizing pessaryrelated complications while taking into consideration patient burden, access to care, and cost to the individuals and the society as a whole.
